Dra. Mennickent-Barros, Daniela

Berberis microphylla G Forst (Calafate) have been used in traditional medicine from prehispanic times in Patagonia. In the last decade the consumption of the fruit has been increased due to their antioxidant capacity, and because several studies demonstrated health benefits associated with the protection against atherosclerosis and other metabolic diseases. Nevertheless, the bioactivity properties of the leaves, a by-product of agronomic management, have been poorly studied. Recently, 108 compounds mainly hydroxycinnamic acids, flavonols, and berberine were identified in a methanolic extract of the leaves, demonstrating great potential for the development of new functional beverages. Based on these, for first time a comprehensive chemical characterization and bioactivity was evaluated for a Calafate leaves infusion prepared in hot water. For this, chemical characterization of the infusion was performed by UHPLC-Q-TOF and TXRF. Bioactivity was assayed by antioxidant capacity, cell cytotoxicity, and cell oxidative stress assays. Inhibition of both Aβ aggregation for Alzheimer's disease and gastrointestinal enzymes for metabolic syndromes were evaluated. The results show that the infusion is rich in hydroxycinnamic acids and other bioactive compounds. The infusion does not contain toxic metals or cytotoxicity activity. The infusion can reduce intracellular reactive oxygen species in HUVEC cells and showed a reduction in the Aβ aggregation being a potential beverage for Alzheimer's prevention. Finally, the infusion had in-vitro hypoglycemic and hypolipidemic effects. These results support the usage of Berberis microphylla G Forst leaves as a new functional beverage.

Alzheimer’s disease (AD) is a neurodegenerative pathology, which is characterized by progressive and irreversible cognitive impairment. Most of the neuronal perturbations described in AD can be associated with soluble amyloid– β oligomers (SO-Aβ). There is a large amount of evidence demonstrating the neuroprotective effect of Nicotine neurotransmission in AD, mainly through nicotinic acetylcholine receptor (nAChR) activation and antiapoptotic PI3K/Akt/Bcl–2 pathway signaling. Using HPLC and GC/MS, we isolated and characterized two alkaloids obtained from C. scoparius, Lupanine (Lup), and 17– oxo-sparteine (17– ox), and examined their neuroprotective properties in a cellular model of SO-Aβ toxicity. Our results showed that Lup and 17– ox (both at 0.03μM) prevented SO-Aβ-induced toxicity in PC12 cells (Lup: 64±7%; 17– ox: 57±6%). Similar results were seen in hippocampal neurons where these alkaloids prevented SO-Aβ neurotoxicity (Lup: 57±2%; 17– ox: 52±3%) and increased the frequency of spontaneous calcium transients (Lup: 60±4%; 17– Ox: 40±3%), suggesting an enhancing effect on neural network activity and synaptic activity potentiation. All of the neuroprotective effects elicited by both alkaloids were completely blocked by α-bungarotoxin. Additionally, we observed that the presence of both Lup and 17– ox increased Akt phosphorylation levels (52±4% and 35±7%, respectively) in cells treated with SO-Aβ (3 h). Taken together, our results suggest that the activation of nAChR by Lup and 17– ox induces neuroprotection in different cellular models, and appears to be an interesting target for the development of new pharmacological tools and strategies against AD.

Amyloid beta peptide (Aβ) is tightly associated with the physiopathology of Alzheimer’s Disease (AD) as one of the most important factors in the evolution of the pathology. In this context, we previously reported that Aβ increases the expression of ionotropic purinergic receptor 2 (P2×2R). However, its role on the cellular and molecular Aβ toxicity is unknown, especially in human brain of AD patients. Using cellular and molecular approaches in hippocampal neurons, PC12 cells, and human brain samples of patients with AD, we evaluated the participation of P2×2R in the physiopathology of AD. Here, we reported that Aβ oligomers (Aβo) increased P2×2 levels in mice hippocampal neurons, and that this receptor increases at late Braak stages of AD patients. Aβo also increases the colocalization of APP with Rab5, an early endosomes marker, and decreased the nuclear/cytoplasmic ratio of Fe65 and PGC-1α immunoreactivity. The overexpression in PC12 cells of P2×2a, but not P2×2b, replicated these changes in Fe65 and PGC-1α; however, both overexpressed isoforms increased levels of Aβ. Taken together, these data suggest that P2×2 is upregulated in AD and it could be a key potentiator of the physiopathology of Aβ. Our results point to a possible participation in a toxic cycle that increases Aβ production, Ca2+ overload, and a decrease of PGC-1α. These novel findings put the P2×2R as a key novel pharmacological target to develop new therapeutic strategies to treat Alzheimer’s Disease.